Generic Name: dolutegravir + abacavir + lamivudine

Pronunciation: TRY-u-meck

Abbreviation: Trii

Other Market Name: N/A

Drug Class: Single-Tablet Regimens

Company: ViiV Healthcare

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Triumeq is approved as first-line therapy for previously untreated people living with HIV, as well as for those with an undetectable viral load who wish to switch to a new regimen.

Triumeq is a recommended treatment option according to the U.S. Department of Health and Human Services (DHHS) Antiretroviral Guidelines for Adults and Adolescents. Visit https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0 for the full DHHS guidelines.


General Info

Triumeq is a single-tablet regimen for HIV. It contains three different types of HIV drugs: one integrase inhibitor and two nucleoside reverse transcriptase inhibitors. Triumeq was approved by the U.S. Food and Drug Administration in August 2014.

Triumeq is a combination of three drugs: Tivicay (dolutegravir), Ziagen (abacavir) and Epivir (lamivudine). All three drugs can be purchased individually for use in combination with other HIV drugs.


Triumeq is considered to be a complete one-pill, once-daily HIV treatment regimen for HIV-positive people whose virus is fully sensitive to integrase inhibitors, abacavir and lamivudine.


Dosage

Adult Dose: One tablet once a day. Each tablet contains 50 mg dolutegravir, 600 mg abacavir, and 300 mg lamivudine.

Triumeq alone is not recommended for people with known HIV resistance to abacavir, lamivudine or any of the approved integrase inhibitors.

Pediatric Dose: N/A

Dosing Info: This is a complete one-pill, once-daily drug regimen. Take with or without food. Contains abacavir and should only be used by patients who have tested negative for HLA-B*5701 (see below).


Side Effects

Common side effects among people using Triumeq including trouble sleeping, headache, tiredness.

Regimens containing abacavir can cause serious and potentially life-threatening allergic (hypersensitivity) reactions. Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701. Your healthcare provider can determine with a blood test if you have this gene variation. Symptoms of hypersensitivity reaction may include fever, rash, nausea, vomiting, diarrhea, abdominal pain, malaise, fatigue, or respiratory symptoms such as sore throat, cough, or shortness of breath.

Some studies suggest that current or recent use of regimens containing abacavir can increase the risk of a heart attack. However, this risk has not been confirmed by other studies.


Drug Interactions

For an overview of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Triumeq or may require dose adjustments, consult the Triumeq package insert.


Other Info

Before taking this medication, tell your doctor if you have kidney disease, liver disease, or any previous experience with a regimen containing abacavir. In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.


For More Info: https://www.gsksource.com/gskprm/htdocs/documents/TRIUMEQ-PI-MG.PDF

Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Last Reviewed: August 7, 2019